APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling

Russell D Petty, Leslie M Samuel, Graeme I Murray, Graham MacDonald, Terrence O'Kelly, Malcolm Loudon, Norman Binnie, Emad Aly, Aileen McKinlay, Weiguang Wang, Fiona Gilbert, Scot Semple, Elaina S R Collie-Duguid, Scott Semple

Research output: Contribution to journalArticlepeer-review

Abstract

5-Fluorouracil(5FU) and oral analogues, such as capecitabine, remain one of the most useful agents for the treatment of colorectal adenocarcinoma. Low toxicity and convenience of administration facilitate use, however clinical resistance is a major limitation. Investigation has failed to fully explain the molecular mechanisms of resistance and no clinically useful predictive biomarkers for 5FU resistance have been identified. We investigated the molecular mechanisms of clinical 5FU resistance in colorectal adenocarcinoma patients in a prospective biomarker discovery project utilising gene expression profiling. The aim was to identify novel 5FU resistance mechanisms and qualify these as candidate biomarkers and therapeutic targets.
Original languageEnglish
Pages (from-to)434
JournalBMC Cancer
Volume9
DOIs
Publication statusPublished - 2009

Fingerprint

Dive into the research topics of 'APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling'. Together they form a unique fingerprint.

Cite this